CRMD
CorMedix Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 5 ▲ CorMedix reported strong Q4 2025 financial results with $128.6 milli…
- Mar 5 ▲ CorMedix reported strong Q4 and full-year 2025 results, driven by $1…
- Mar 20 In re CorMedix Inc. Derivative Litigation
- Apr 27 ▲ CorMedix announced positive topline results from its Phase III ReSPE…
- Apr 27 ▲ CorMedix announced positive Phase III topline results from the ReSPE…
- Jun 12 ▲ A strong institutional cluster formed in CRMD during Q4 2024, with 8…
- Sep 23 Oppenheimer initiates
- Oct 19 ▲ CorMedix announced that the FDA has accepted for filing and granted…
- Oct 19 ▲ CorMedix announced FDA acceptance of its sNDA for REZZAYO (rezafungi…
- Nov 9 CorMedix entered into a loan agreement with BioPharma Credit for up…
- Nov 10 CorMedix announced a definitive agreement to acquire substantially a…
- Nov 12 ▼ Earnings: CRMD Q3 2026 Earnings: EPS $-0.19 (-62.0% vs est)
- Nov 13 New insider trade: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersLOCKED
1 open-market trade filed or updated in the last 24 hours. 🔒 Subscribers only.
- InstitutionsBULLISH
Q3 2026: 22 added (0 new), 10 trimmed or exited.
- AnalystsBULLISH
11 of 12 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.132 → −$0.160 over 90 days. 0 up, 2 down in 30 days.
- Short sellersSTEADY
Short interest −3.1% to 14.21M shares. 8.4 days to cover, ≈18.2% of shares.
- TrendDOWNTREND
32% below its 50-day average. New closing low $4.66 on Nov 13.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 8.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| AMERICAN CENTURY COMPANIES INC | DOUBLED | $21.0M |
| MARSHALL WACE, LLP | ADD | $9.2M |
| MORGAN STANLEY | ADD | $4.9M |
| FIRST TRUST ADVISORS LP | DOUBLED | $2.6M |
| JPMORGAN CHASE & CO | DOUBLED | $2.1M |
| Quantinno Capital Management LP | ADD | $1.5M |
| Private Advisor Group, LLC | TRIM | $1.2M |
| LPL Financial LLC | TRIM | $725.3K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analystsPrice is below the lowest target. Median implies +170%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Oppenheimer REITERATE | Outperform |
| Nov 13, 2026 | RBC Capital MAINTAIN | Outperform |
| Nov 12, 2026 | Needham MAINTAIN | Buy |
| Nov 10, 2026 | RBC Capital MAINTAIN | Outperform |
| Nov 10, 2026 | Needham MAINTAIN | Buy |
| Nov 2, 2026 | Needham MAINTAIN | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
| 🔒 Fresh data, subscribers only Nov 13, 2026 | BUY | |
Dillione Janet Director Sep 18, 2026 | EXERCISE | 48,909 sh |
Hurlburt Elizabeth Chief Operating Officer Aug 29, 2026 | TAX W/H | $67.0K |
Blum Susan Chief Financial Officer Aug 29, 2026 | TAX W/H | $69.9K |
Zelnick Kaufman Beth Chief Legal Officer Aug 29, 2026 | TAX W/H | $69.9K |
Todisco Joseph Chief Executive Officer Feb 4, 2026 | AWARD | 77,156 sh |
Zelnick Kaufman Beth Chief Legal Officer Feb 4, 2026 | AWARD | 36,006 sh |
Hurlburt Elizabeth Chief Operating Officer Feb 4, 2026 | AWARD | 36,006 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.16 | -$0.25–-$0.09 | -23.1% | $51.6M |
| Next Q | -$0.06 | -$0.06–-$0.06 | -200.0% | $68.2M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
17 filings · 4 press releases · 8 bullish · 1 bearish · 8 neutral- BEARISH PRESS-RELEASENov 12, 2026
CorMedix reported Q3 2026 consolidated revenue of $54.5M, above consensus of $52.8M, but GAAP net…
Monitor the Heron acquisition closing timeline and integration progress, as well as CMS reimbursement framework updates that could affect DefenCath pricing and utilization in 2027.
- NEUTRAL DEFA14ANov 10, 2026
CorMedix announced a definitive agreement to acquire substantially all assets of Heron…
Monitor Heron stockholder vote and regulatory clearance for Q1 2027 close. Watch for integration execution and whether the $45M-$60M synergy target is achieved by year-end 2027. Track ZYNRELEF sales…
- BULLISH 8-KNov 10, 2026
CorMedix announced a definitive agreement to acquire substantially all assets of Heron…
Monitor Heron stockholder vote and regulatory clearance timeline for Q1 2027 close. Track ZYNRELEF sales trajectory toward 2028 earn-out thresholds ($65M and $95M). Watch CINVANTI competitive…
- NEUTRAL DEFA14ANov 9, 2026
CorMedix entered into a loan agreement with BioPharma Credit for up to $50M in Tranche B term…
Monitor Heron stockholder vote and regulatory clearances for the asset purchase. The combined entity will have four additional commercial products, significantly expanding CorMedix's revenue base…
All CRMD filing & press-release reports (21)
- PRESS-RELEASE reportNov 12, 2026
- DEFA14A reportNov 10, 2026
- 8-K reportNov 10, 2026
- DEFA14A reportNov 9, 2026
- 8-K reportNov 9, 2026
- 8-K reportNov 2, 2026
- PRESS-RELEASE reportNov 2, 2026
- 8-K reportOct 19, 2026
- PRESS-RELEASE reportOct 19, 2026
- PRESS-RELEASE reportAug 13, 2026
- 8-K reportAug 13, 2026
- 8-K reportJul 1, 2026
- INST-CLUSTER reportJun 12, 2026
- 8-K reportJun 8, 2026
- PRESS-RELEASE reportJun 8, 2026
- 8-K reportMay 14, 2026
- PRESS-RELEASE reportMay 14, 2026
- 8-K reportApr 27, 2026
- PRESS-RELEASE reportApr 27, 2026
- 8-K reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026